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Background: The human OXR1 gene belongs to a class of genes with conserved functions that protect cells from
reactive oxygen species (ROS). The gene was found using a screen of a human cDNA library by its ability to
suppress the spontaneous mutator phenotype of an E. coli mutH nth strain. The function of OXR1 is unknown. The
human and yeast genes are induced by oxidative stress and targeted to the mitochondria; the yeast gene is
required for resistance to hydrogen peroxide. Multiple spliced isoforms are expressed in a variety of human tissues,
including brain.
Results: In this report, we use a papillation assay that measures spontaneous mutagenesis of an E. coli mutM mutY
strain, a host defective for oxidative DNA repair. Papillation frequencies with this strain are dependent upon a G!T
transversion in the lacZ gene (a mutation known to occur as a result of oxidative damage) and are suppressed by
in vivo expression of human OXR1. N-terminal, C-terminal and internal deletions of the OXR1 gene were
constructed and tested for suppression of the mutagenic phenotype of the mutM mutY strain. We find that the
TLDc domain, encoded by the final four exons of the OXR1 gene, is not required for papillation suppression in E.
coli. Instead, we show that the protein segment encoded by exon 8 of OXR1 is responsible for the suppression of
oxidative damage in E. coli.
Conclusion: The protein segment encoded by OXR1 exon 8 plays an important role in the anti-oxidative function
of the human OXR1 protein. This result suggests that the TLDc domain, found in OXR1 exons 12–16 and common
in many proteins with nuclear function, has an alternate (undefined) role other than oxidative repair.Background
Respiratory metabolism generates reactive oxygen spe-
cies (ROS) that can damage many cellular components
such as DNA, proteins and lipids [1-3]. These ROS in-
clude such molecules as superoxide, singlet oxygen, hy-
droxyl radicals, and hydrogen peroxide, which can be
produced as by-products of aerobic metabolism, oxidor-
eductase enzymes and metal-catalyzed oxidations.
Hydrogen peroxide, while relatively stable, can react
with Fe2+ via the Fenton reaction to produce hydroxyl
radicals [4]. ROS also play a role in cell signaling, where
they can be involved in apoptotic processes, transcrip-
tional activation or suppression programs, and cell sig-
naling cascades [5]. An increasing number of human* Correspondence: michael.volkert@umassmed.edu
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distribution, and reproduction in any mediumdiseases are associated with the damage that ROS cause,
including cancer, autoimmune diseases, hypertension
and neurodegenerative diseases [3,6-10]. Oxidative dam-
age is also considered a major factor in the mechanisms
of aging and age-related diseases such as Parkinson’s and
Alzheimer’s [11-13].
There are two modes of action that cells can use to
combat the deleterious effects of ROS on cellular consti-
tuents: ROS prevention and DNA repair. The first
includes molecules that inactivate or inhibit the forma-
tion of ROS, thus preventing damage from occurring in
the cell. Such detoxification molecules include enzymes
like superoxide dismutase, catalase, and glutathione per-
oxidase [14,15], metabolites such as beta-carotene, lyco-
pene and vitamins A, C and E, and minerals such as
selenium and manganese [16]. These systems either pre-
vent ROS from forming or scavenge them before theyCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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second means of defense against ROS involves DNA re-
pair enzymes that correct chromosomal damage caused
by ROS if they are not inactivated [17]. These enzymes
are primarily components of the base excision repair
(BER) pathways in both Escherichia coli and higher
eukaryotes, though nucleotide excision repair (NER),
mismatch repair (MMR), and strand break repair
mechanisms are also involved in repair of oxidative dam-
age [18,19].
The 8-oxoG modified base is a frequent oxidation
product of guanine that is used as a biomarker of oxida-
tive DNA damage [20]. In E. coli, 8-oxoG pairs with
adenine during replication, resulting in a G!T transver-
sion if the lesion is not repaired. The MutM glycosylase
(aka Fpg) functions to remove 8-oxoG from DNA,
whereas the MutY protein removes the adenine opposite
8-oxoG, giving more time for MutM to work prior to
replication [21]. Nth (endonuclease III) and Nei
(endonuclease VIII) are two other glycosylases that act
principally on the damaged pyrimidines [22]. E. coli
mutants in most of these genes, either confer sensitivity
to exogenous peroxide treatment, and/or display a spon-
taneous mutator phenotype as a result of their inability
to repair spontaneous oxidative damage. Mammalian
homologs of these glycosylases have also been described
and are an area of intense study [23].
In a previous study using a human cDNA library to
identify eukaryotic genes that either prevent or repair
oxidative damage, the OXR1 gene was identified by its
ability to suppress the spontaneous mutator phenotype
of an E. coli nth mutH strain [24]. The OXR1 function is
highly conserved among eukaryotes, but is not found in
prokaryotes. A deletion of the OXR1 gene in
Saccharomyces cerevisiae causes an increase in sensitivity
to hydrogen peroxide [24], and removal of a locus en-
coding all seven isoforms in Drosophila melanogaster
results in lethality due to a defect in eclosion (hatching)
[25]. Silencing of OXR1 mRNA by 83% sensitized mos-
quitoes to the harmful effects of hydrogen peroxide in
their drinking water. Interestingly, the silencing of
OXR1 also resulted in decreased mRNA levels for both
catalase and glutathione peroxidase, suggesting that (at
least in insects) OXR1 may have a regulatory role in re-
sistance to ROS [26]. A study examining the expression
of OXR1 in the mouse retinal cells after exposure to
high levels of oxygen showed that OXR1 expression was
increased by 3 days exposure, when photocells were re-
sistant to hyperoxia and remained high in the strain that
was resistant to hyperoxia. In the sensitive strain of
mice, OXR1 levels declined in the retina and the photo-
cells started to degenerate [27]. Transgenic mice expres-
sing the human ApoE-E4 isoform of apolipoprotein
ApoE have been characterized as exhibiting structuraland functional abnormalities in their mitochondria [28-
30]. A recent proteomic analysis of hippocampal cells
from these mice identified OXR1 as one of the mito-
chondrial targeted gene products specifically downregu-
lated following an ischemic insult [31]. By contrast, the
hippocampus cells from mice transgenic for ApoE-E3
did not show mitochondrial abnormalities and did not
exhibit a reduction for OXR1 transcripts following ische-
mic insult.
A recent report shows that the Bella mouse (bel), iden-
tified in a screen for mouse models of human movement
disorders, lacks the OXR1 gene. These mice develop
normally for 2 weeks following birth, but soon thereafter
develop severe ataxia, do not show normal weight gain,
and die within a month [32]. The pathological properties
of the bel mutant mouse were reversed by an OXR1
transgene, confirming that loss of OXR1 was responsible
for these neurological defects. Histological analyses of
these mice show increased cell death in the granular cell
(GC) layer of the cerebellum. These authors also report
that OXR1 is overexpressed in amyotrophic lateral scler-
osis (ALS) patients and in mouse models of ALS, indi-
cating a possible protective function of OXR1 in this
neurodegenerative disorder. Both the human and yeast
OXR1 genes are induced by heat and oxidative stress,
and their proteins localize to the mitochondria [33].
Localization of the OXR1 protein to mitochondria is sig-
nificant since this organelle represents a major source of
ROS production in the cell.
A bacterial papillation assay for OXR1 activity has
been previously described [34,35]. It utilizes a strain con-
taining the lacZ cc104 allele [36] in an E. coli mutM
mutY strain [21]. In this background, the lacZ cc104
mutation spontaneously reverts at high frequency to
wild type by a GC! TA transversion (a common muta-
tion found in DNA exposed to oxidizing agents). Over-
expression of mutM alone completely eliminates
GC!TA transversions in this strain, indicating they are
primarily due to lesions repaired by the MutM glycosy-
lase, predominantly 8 oxoG [34,35]. Thus, by growth of
colonies on minimal lactose plates containing Xgal and
IPTG, isolated colonies show high levels of Lac + papil-
lae. The expression of OXR1 suppresses oxidative dam-
age, which can be easily detected by a lower frequency
of papillation in this genetic background. In this study,
we use this papillation assay to identify which region of
the OXR1 protein is important for this suppressive func-
tion. Surprisingly, we find that the highly conserved
TLDc domain, found in the extreme C-terminal region
of most of the OXR1 isoforms, is not required for sup-
pression of mutagenic activity in E. coli. Instead, the oxi-
dation resistance function is located in a region of OXR1
encoded by exon 8, in a segment of the gene that
encodes a putative helix-turn-helix structural motif.
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Numbering of the OXR1 protein
The original OXR1-producing plasmid pMV520 was
identified from a library of human cDNAs cloned into
pSE380 [24]. In this construct, the OXR1 DNA sequence
starts with codon 200 of exon 7 (shaded lysine in
Figure 1) and includes all downstream exons through
exon 16, with the exception of exon 10. The start site
for OXR1 protein expression from pMV520 is most
likely the downstream ATG codon within exon 7 at pos-
ition 225 (shaded methionine in Figure 1). This pro-
posed N-terminal end for OXR1 encoded by pMV520
is based on the following observations. First, there is an
ATG site in the vector (42 base pairs upstream of the
OXR1 sequence) that is a potential translational start
site for OXR1. There is an ATG site in the vector
(42 base pairs upstream of the OXR1 sequence) that is aExon Protein sequence     
7            
8 SSALLKEKQRHRLHKFLCLRVGKPMRKTFVSQA
9 TDHLYAFFIQWSPEIYAEDTGEYTREPGFIVVKKI
10 MSRLWYGKKGRRHQPINHKYTL   











Figure 1 The human OXR1 gene. Top: The genomic structure of OXR1 c
portions of exons shown in black are present in an oxidation resistance act
are known to be dispensable for this activity. Exon 10 is found in a variant
Bottom: The protein sequences encoded by OXR1 exons 7 through 16 are
truncations were constructed by placing an ATG at the codon prior to pos
position 225 (shaded) in exon 7, or by placing an ATG start codon in front
(except exon 10). The end points for the series of OXR1 C-terminal truncati
found in pMV520; it is shown here for completeness.potential translational start site for OXR1. If used, it
would generate an OXR1 protein that has an additional
13 amino acids (encoded by the vector) fused to the N-
terminus of OXR1. However, removal of this putative
start site (in pMV1248) did not affect the size of the
OXR1 protein produced relative to that by encoded by
pMV520 (as determined by SDS-PAGE; see section on
C-terminal OXR1 deletions described below). This
result strongly suggests that the ATG sequence within
the vector is not the start site for OXR1 translation in
pMV520. Secondly, the vector-encoded start codon in
pMV520 is preceded by an in-frame stop codon 15 base
pairs upstream and does not have a correctly positioned
ribosome binding site preceding it, making it an unlikely
start site for translation. Finally, when a construct is
made that places an ATG start site in front of codon
200 of exon 7 (pMV1260), an OXR1 product of larger      Total residues 
                255 
SATMQQYAQRDKKHEYWFAVPQER  57 
EESETIEDSSNQAAAREWE   54 
      22 
      27 
LPDQIEK      42 
TGLDTPVLMVIKDSDGQ   51 
      33 
      24 





onsists of 16 known exons located on chromosome 8q23. Exons, or
ive form of OXR1 previously described [24], whereas exons in white
that begins with exon 10 and includes exons 12 through 15 [43].
listed. The starting points for the series of OXR1 N-terminal
ition 203 (shaded lysine) of exon 7, using the methionine codon at
of the codons encoding the first residues listed for exons 8 through 13
ons are denoted by the arrows. Exon 10 is listed here, but was not
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(data not shown).
These results strongly suggest that OXR1 made from
pMV520 starts downstream of the lysine at codon pos-
ition 200 of exon 7. Thus, the methionine encoded at
position 225 of OXR1 exon 7 is designated as the first
amino acid residue of “full length” OXR1 protein pro-
duced from pMV520 (see Figure 1). This full-length des-
ignation is only in respect to the region of OXR1 that is
responsible for the anti-oxidant activity identified by the
papillation assay in these experiments. Splice variants
that carry exons not examined here (exons 1–6) may
have additional functions, some of which may or may
not be involved in oxidative repair. All exons listed in
Figure 1, except the first 199 codons of exon 7 and exon
10, are found in the pMV520. Exon 10 is used as an al-
ternative starting point for a splice variant that includes
exons 10 and 12 through 16, which has no detectable
oxidation antimutator activity (data not shown).
OXR1 N-terminal deletions
A series of plasmids containing N-terminal deletions of
the OXR1 gene was transformed into strain MV4709
(mutM mutY) and tested for suppression of G!T trans-
versions using the papillation assay described above. In
these constructs, OXR1 is driven by Pmac, an artificial
promoter designed to express genes under the control of
IPTG (see Methods section). The plasmids also encode
the lacI repressor. As seen in Figure 2B, plasmids
pMV1260 and pMV1263 that overexpress full-length
OXR1 protein show a reduced plating efficiency upon
induction, indicating they are toxic to E. coli in the pres-
ence of 1 mM IPTG. (In addition, pMV1260 also pro-
duces a larger protein that is generated by the
transcription of sequences present, but not expressed, in
pMV520; see legend to Figure 2A). A reduced plating ef-
ficiency was also observed for IPTG induction of cells
containing pMV1266, which is missing all of exon 7, and
produces an OXR1 N-terminal truncation starting with
exon 8 sequences. However, suppression of papillation is
still observed among the colonies that do survive con-
taining these three plasmids. On the contrary, OXR1
constructs starting with exons 9 or 12 (pMV1269 and
pMV1275) are not toxic to E. coli upon IPTG induction
and were unable to suppress the papillation phenotype.
These results suggest that exon 8 is important for the
mutagenic suppressor activity of OXR1, and/or the sta-
bility of the OXR1 protein.
As is apparent in Figure 2B, constructs pMV1260,
pMV1263 and pMV1266 all show decreased colony
forming ability relative to the non-suppressing plasmids
in the presence of IPTG. This effect is observed despite
the fact that these plasmids encode the lacI repressor.
The ability of these plasmids to suppress the mutagenicphenotype of MV4709 may be due to the lower viability
(or slower growth rate) due to overexpression of a toxic
protein. To control the amount of OXR1 deletion frag-
ments produced in vivo, strain MV4709 containing these
plasmids were transformed with a compatible plasmid
overexpressing the LacI repressor (pMS421), resulting in
higher levels of LacI repressor being present (relative to
cells expressing lacI from only the Oxr1-expressing plas-
mids). As shown in Figure 2C, this increase in LacI re-
pressor protein expression in vivo had the effect of
eliminating the toxicity effect of these plasmids when
plated in the presence of 1 mM IPTG, without eliminat-
ing the suppressive effects of OXR1 expression on papil-
lation (except pMV1263; discussed below). The
papillation assay in this background shows that a con-
struct expressing OXR1 starting at exon 8 (pMV1266)
suppresses the mutagenic phenotype of MV4709 without
causing toxicity. As before, constructs starting at exons
9, 11 or 12 did not exhibit any suppressor activity.
The lack of papillation suppression by the OXR1 frag-
ment encoded by pMV1269, pMV1272, and pMV1275,
might be due to differential expression of the OXR1 de-
letion mutant proteins. Thus, extracts of cells containing
these constructs were run on SDS-PAGE. As seen in
Figure 2D, one observes a decrease in OXR1 fragment
production upon loss of exon 8 (compare lanes 3 and 4),
suggesting the importance of the protein domain
encoded by exon 8 in OXR1 stability in E. coli. While
the decrease in protein production seen with OXR1
(9–16) probably explains the loss of toxicity observed
with pMV1269 in Figure 2B, we do not believe that this
decrease in protein level can explain the inability of
OXR1 (9–16) to suppress papillation. This conclusion is
based on the observation that similar levels of protein
are seen in extracts of cells expressing full length OXR1
from pMV520 (which suppresses papillation) and the
OXR1(9–16) fragment from plasmid pMV1269 (which
does not suppress papillation – see arrows in Figure 2E).
Thus, enough OXR(9–16) fragment is present in cells
containing pMV1269 that if it did contain OXR1’s oxida-
tion resistance activity, it would suppress the mutagenic
phenotype of MV4709 host cells. Plasmid pMV1272 pro-
duces an OXR1 fragment starting at exon 11 and
encodes a stable protein but is unable to suppress papil-
lation, while a construct encoding an OXR1 fragment
starting at exon 12 (pMV1275) did not produce a stable
protein (Figure 2D, lanes 5 & 6, respectively). Finally, a
construct expressing only exons 13-16 (pMV1278) also
did not show suppression of papillation activity, al-
though it did show a stable protein fragment when
extracts were run on SDS-PAGE (data not shown).
Overall, these results show that exons 9–16 are not
required for the oxidation resistance activity exhibited
by full length OXR1. This result was a little surprising,
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Figure 2 (A) Diagram of N-terminal deletions of OXR1. In these assays, the full-length OXR1 construct is represented by both pMV1263,
which starts with methionine 225 in exon 7 (the expected start site of OXR1 in pMV520) and pMV1260, which encodes both this species and a
slightly larger OXR1 species (by virtue of the presence of an initiating methionine start site inserted prior to codon 200 in exon 7). (B) Papillation
assay for full-length OXR1 species (pMV1260 and pMV1263) and three N-terminal deletions starting within exon 8 (pMV1266), exon 9 (pMV1269)
and exon 12 (pMV1275). Plasmids were expressed in strain MV4709 (mutM mutY lacZ cc104) and plated on minimal lactose plates containing
100 μg/ml carbenicillin with and without 1 mM IPTG. Aliquots of 10-fold serial dilutions are plated beginning with undiluted cells on the left. No
OXR1 controls containing pBR322 showed patterns that were identical to pMV1269 and p1275 (not shown). (C) Papillation assay for full-length
OXR1 species (pMV1260 and pMV1263) and three N-terminal deletions starting within exon 8 (pMV1266), exon 9 (pMV1269) and exon 12
(pMV1275). Plasmids were expressed in strain MV4709 (mutM mutY lacZ cc104) containing pMS421 (LacI-producer) and plated on minimal lactose
plates containing 100 μg/ml carbenicillin, 40 μg/ml streptomycin, 20 μg/ml spectinomycin and 1 mM IPTG. (D) SDS-PAGE of extracts containing
plasmids expressing OXR1 N-terminal deletions. Plasmid pMV1263 makes the full-length OXR1 species encoded by pMV520, while pMV1260
makes both this species and a slightly larger one that starts at position Lys-200 in exon 7. In addition, the arrows denote positions of observed
protein bands for pMV1269 and pMV1272. (E) SDS-PAGE comparing full length OXR1 (pMV520) and OXR1 fragment starting at exon 9 (pMV1269).
Arrows denote positions of induced protein bands; full length OXR1 is present as a doublet (see text for details).
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among comparisons to other OXR1 variants [24] and
contains a conserved protein domain found in a number
of eukaryotic proteins with nuclear function - the TLDc
domain [37].
One other interesting feature is apparent in the results
shown in Figure 2C. Under these conditions of limited
expression of these OXR1 constructs, the plasmidpMV1263 did not exhibit suppressor activity, even
though a plasmid missing an additional 31 residues
(pMV1266) did show suppressor activity. This result is
not due to a mutation in pMV1263, as sequencing of the
promoter and OXR1 region of this construct did not
reveal any differences relative to the wild type sequences.
Furthermore, this differential suppression is not due to
different levels of expression of the OXR1 fragments in
Murphy and Volkert BMC Molecular Biology 2012, 13:26 Page 6 of 15
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similar levels of protein expression on SDS-PAGE gels
(see Figure 2D, compare lanes 2 and 3). One possibility
for this observation is that the last 25 amino acid
residues encoded by exon 7 may contain a control seg-
ment for OXR1 activity, which when exposed by re-
moval of exon 7 residues 203–224, results in inhibition
of the suppressor activity encoded within exon 8. Note
however, that this inhibition can be relieved by further
overexpression of this particular construct (when the
LacI overproducer is absent - see Figure 2B). Further
biochemical and mutational analysis of OXR1 activity
within this region will be needed to verify this
hypothesis. In addition, this result demonstrates that
overproduction of a foreign protein does not in itself
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Figure 3 (A) Diagram of C-terminal deletions of OXR1.
(B) Papillation assays with plasmids expressing OXR1 C-terminal
deletions in MV4709 containing LacI-producing plasmid pMS421.
Dilutions and cell platings were as in Figure 2B using plates
containing 0.125 mM and 1.0 mM IPTG on minimal lactose plates
containing 100 μg/ml carbenicillin, 40 μg/ml streptomycin and
20 μg/ml spectinomycin. (C) SDS-PAGE of extracts containing
plasmids expressing OXR1 C-terminal deletions.C-terminal deletions of OXR1
Carboxy-terminal deletions of OXR1 were constructed
to identify what distal exons of OXR1 are important for
activity and/or stability of the protein. These plasmids
are controlled by the IPTG-inducible Ptrc promoter; the
OXR1 sequence starts at position 200 in exon 7 in all
the constructs. As described previously, translation from
these plasmids most likely initiates with the methionine
at position 225 of exon 7. The C-terminal encoding end-
points in these plasmids are found at various points be-
tween exons 12 and 16 (see arrows in Figure 1). After
transformation into MV4709 containing the LacI-
producing plasmid pMS421, the ability of these con-
structs to suppress mutagenesis was assessed by the
papillation assay.
As can be seen in Figure 3B, all four of the OXR1 C-
terminal deletions were capable of suppressing papilla-
tion when plated in the presence of 0.125 mM IPTG. At
1.0 mM IPTG, overexpression of these OXR1 fragments
caused toxicity. Interestingly, overexpression of these
OXR1 fragments with 1 mM IPTG prevented suppres-
sion when high amounts of cells were plated, but still
showed suppression of papillation when single colonies
were examined (see Figure 3B). This effect was not
observed when toxic levels of the N-terminal fragments
were plated (see Figure 2B). (The toxicity seen when the
C-terminal deletions were plated with 1 mM IPTG in
strain MV4709 containing pMV421, but not with the N-
terminal deletions described above (Figure 2C), is likely
the result of the higher transcriptional activity of the Ptrc
promoter relative to Pmac.) Thus, removal of OXR1
exons 13–16 (including the TLDc domain) had no effect
on the ability of these fragments to suppress papillation
(and thus oxidative damage), consistent with the results
from the N-terminal deletion constructs described
above.
Extracts of MV4709/pMS421 cells expressing these
fragments were run on SDS-PAGE to examine the level
of proteins produced. As seen in Figure 3C (lane 2), a
doublet band is observed for the full length OXR1
expressed from pMV520. Given the close spacing of
these bands, the difference in size between them is likely
to be about 1–2 kDa. The doublet band of OXR1 is also
observed in a second full-length OXR1 construct that
promotes higher levels of protein (pMV1248 – see
Figure 3C, lane 3) and with all four of the OXR1 C-
terminal deletion constructs (see Figure 3C, lanes 4–7).
Thus, the most likely explanations for the OXR1 doublet
is either (1) a second restart site at the GTG site 13
codons downstream of the ATG start site, or (2) in vivo
degradation of 10–20 amino acids from the N-terminus.
A construct that initiates from a start codon placed at
the beginning of exon 8 encodes a single discrete species
(Figure 2D, lane 3). Thus, if the doublet is due to partial
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the last 31 residues of exon 7.
Internal deletions of OXR1 fragment containing OXR1
exons 8–13
Plasmid pMV1282 encodes OXR1 exons 8, 9, 11, 12 and
13 driven by the Pmac promoter (see Methods section).
A high level of expression of the OXR1 fragment was
observed from extracts of IPTG-induced cells containing
this plasmid (data no shown). Overexpression of this





























Figure 4 (A) Diagram of internal-terminal deletions of OXR1
(8–13). (B) Papillation assays with plasmids expressing OXR1 internal
deletions in MV4709 containing LacI-producing plasmid pMS421.
Dilutions and cell platings were as in Figure 2B using plates
containing 1.0 mM IPTG on minimal lactose plates containing
100 μg/ml carbenicillin, 40 μg/ml streptomycin and 20 μg/ml
spectinomycin. (C) SDS-PAGE of extracts containing plasmids
expressing OXR1 internal deletions.the N-terminal series of deletions described above). To
down-regulate the expression of the OXR1 fragment
encoded by pMV1282, rrnB T1 and T2 terminators were
removed by digestion with SacI and XbaI, filling-in with
T4 DNA polymerase and dNTPs, and religating. The
resulting plasmid (pMV1293) showed lower amounts of
the OXR1 fragment relative to pMV1282 as seen on
SDS-PAGE (data not shown). It is presumed that re-
moval of the terminator sequences from the plasmid
destabilized the resulting transcript. Plasmid pMV1293
expresses exons 8, 9, 11, 12 and thirty-nine out of the
fifty-one residues encoded by exon 13. It suppresses the
mutator phenotype of MV4709/pMS421 (mutM mutY)
when single colonies are examined; see Figure 4B. When
the OXR1 fragment from pMV1293 is expressed in
MV4709/pMS421, a protein band is observed on SDS-
PAGE consistent with the expected size of the OXR1
fragment encoded by these exons (25.6 kDa; see
Figure 4C, lane 2).
A series of plasmids containing in-frame internal dele-
tions of pMV1293 were constructed and tested for their
ability to suppress the papillation of MV4709/pMS421.
Plasmid pMV1294 contains an internal deletion that
removes most of exons 8 and 9. This plasmid did not
produce a stable band on SDS-PAGE, and not surpris-
ingly, did not suppress papillation (Figure 4B & C). This
result suggests that this region of the protein is import-
ant for stability of the OXR1 (8–13) fragment, as noted
above for the N-terminal deletion plasmid pMV1269.
Plasmid pMV1295, which is missing the latter half of
exon 9, exons 11 and 12, did suppress papillation and
showed a band on SDS-PAGE consistent with the size of
the expected fragment (~15 kDa; see Figure 4C, lane 4).
In fact, the suppression exhibited by pMV1295 was
more efficient than that seen with pMV1293, which con-
tains exons 8–13 (see Figure 4B, compare rows 2 and 4).
In this case, papillation suppression was noted when
high numbers of cells were plated (see Figure 4B, row 4).
The only intact exon in pMV1295 is exon 8, showing
again that this domain encodes the active suppressor
function. Finally, a plasmid that contains exons 8–12 but
is missing all but the first 12 residues of exon 13
(pMV1296), still suppressed papillation within single col-
onies, but to a lesser extent than pMV1293 (an effect
likely due to lower amounts of this protein fragment
relative to the OXR1 (8–13); see Figure 4C, compare
lanes 2 and 5, see arrow). The most likely explanation
for this observation is that a stability determinant of this
protein is present in exon 13 and that its presence in
pMV1295 stabilizes exon 8, enhancing its activity.
Internal deletions of full-length OXR1 (8–16)
Given the above results suggesting that exon 8 encodes
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Alignment of protein sequences encoded
by OXR1 exon8 and NCOA7 exon 9 
Figure 5 (A) Secondary structural prediction of the polypeptide encoded by OXR1 exon 8 based on the method of Garnier et al [38].
Boxed region of protein sequence defines the putative larger helix-turn-helix region of the protein. (B) ClustelW alignment of the protein
sequences encoded by OXR1 exon 8 and NCOA7 exon 9.
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tures of the protein fragment encoded by exon 8 was
performed (Figure 5A). Highlighted in this analysis
is a potential helix-turn-helix segment encoded by resi-
dues 9–36 (boxed in Figure 5A), and a second (smaller)
helix-turn-helix segment encoded by residues 38–49.
Understanding that protein secondary structural predic-
tion programs are not definitive, we used these predic-
tions as a guide to generate a second set of internal
deletions of OXR1, this time starting with the full
length construct (containing exons 8–16). Plasmids were
constructed that removed each of these regions separ-
ately (pKM398 and pKM407) and together (pKM406),
as well as deletions in the latter part of exons 8 and 9
(see Figure 6A). Papillation and SDS-PAGE analyses of
these constructs are shown in Figure 6B and 6C,
respectively.
A plasmid (pKM406) that encodes a protein that is
missing both predicted helix-turn-helix structural fea-
tures failed to suppress papillation on plates containing
either 0.1 or 1.0 mM IPTG (Figure 6B, row 4). This re-
sult is due to the lack of significant protein production
seen with this construct (Figure 6C), again arguing for
the presence of a major stability determinant encoded by
exon 8. A plasmid (pKM407) that encodes an OXR1protein that contains the first (larger) predicted
helix-turn-helix encoded by exon 8, but not the second
one, was fully capable of papillation suppression at
0.1 mM IPTG (see Figure 6B, row 5). The construct also
exhibited inhibition of cell growth at higher concentra-
tions of IPTG, as observed with the full length OXR1
protein. A plasmid construct (pKM398) missing the first
predicted helix-turn-helix feature, but containing the
second one, was also tested. This construct was not able
to inhibit papillation at 0.1 mM IPTG, but did so in the
presence of higher amounts of IPTG (See Figure 6B).
SDS-PAGE analysis of extracts of these cells (Figure 6C)
shows that this effect could largely be attributed to the
differences in stable protein production from plasmids
pKM398 and pKM407 (compare lanes 4 & 6 in
Figure 6C), making it hard to assign the supression of
mutagenesis function to principally one or the other re-
gion in exon 8. Nonetheless, these results show that ei-
ther predicted helix-turn helix region of exon 8 is
sufficient to prevent oxidative damage. In addition, the
first predicted helix-turn-helix region of exon 8 encodes
the major stability determinant of the OXR1 protein.
Finally, a plasmid construct encoding OXR1 deleted of
the latter part of exon 8 and the beginning of exon 9










Exon 8  SSALLKEKQRHRLHKFLCLRVGKPMRKTFVSQASATMQQYAQRDKKHEYWFAVPQER
               pKM398 
               pKM406 
               pKM407   
               pKM361 
Exon 9  TDHLYAFFIQWSPEIYAEDTGEYTREPGFIVVKKIEESETIEDSSNQAAAREWE 
               pKM361 


























0.1 mM IPTG  1 mM IPTG
Figure 6 (A) Diagram of internal deletions of exons 8 and 9 within constructs expressing full length OXR1 proteins (exons 8–16). Bars
represent regions of exon 8 that are missing in the OXR1 deletion mutants. (B) Papillation assay for control plasmid (pBR322), an OXR1 encoded
by exons 8–16 (pMV1266), and the five internal deletions of OXR1 diagrammed in part A. Plasmids were expressed in strain MV4709 (mutM mutY
lacZ cc104) containing LacI-producing plasmid pMS421. Dilutions and cell platings were as in Figure 2B using 0.125 mM and 1.0 mM IPTG on
minimal lactose plates containing 100 μg/ml carbenicillin, 40 μg/ml streptomycin and 20 μg/ml spectinomycin. (C) SDS-PAGE comparing full
length OXR1 (pMV1266) and OXR1 deletion mutants described in part A. The expected sizes of the protein fragments from these plasmid are as
follows: pMV1266 (38.2 kDa); pKM398 (35.2 kDa); pKM406 (33.1 kDa); pKM407 (36.5 kDa) pKM394 (36.8 kDa); pKM361 (35.5 kDa).
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proteins that were fully capable of papillation suppression
at 0.1 mM IPTG (Figure 6B and C). These results are in
agreement with those discussed above for N-terminal de-
letion mutants that exon 9 is not involved in oxidative
damage protection.
2A summary of these experiments is shown in Table 1.
It is evident that all the constructs that express a stable
form of OXR1 containing exon 8 are fully (or partially)
capable of suppressing the oxidative mutator effect
exhibited by the tester strain, MV4709 (mutM mutY).
All other deletions have neither an effect on toxicity
(when overexpressed) nor the capability to suppress
papillation. Thus, exon 8 encodes the peptide sequences
required for the oxidative mutagenesis suppression activ-
ity of the human OXR1 protein. Finally, we note that the
exon 8-encoded protein sequence contains a cysteine
residue at position 18, that might be a reactive residue
involved in oxidative damage repair. We tested this pre-
diction by altering Cys-18 of exon 8 to alanine in plas-
mid pMV1266. However, the C18A mutant was as
capable as the wild type OXR1 sequence for suppression
of papillation, ruling out a role for this cysteine residue
in oxidative damage repair or prevention.Quantitative analysis of OXR1 mutation suppression
The papillation assay is very sensitive for detection of
the mutagenic suppression activity of OXR1. Nonethe-
less, we preformed a more quantitative analysis on some
of the OXR1 fragment-producing constructs des-
cribed above. Lac+ reversion frequencies of MV6543
(mutM mutY lacZcc104) were determined by growing
cells overnight and plating on M9 minimal plates con-
taining lactose as the sole carbon source (as described in
the Methods section). In the absence of OXR1, MV6543
generated over 350 Lac+ revertants per 108 cells plated
(see Figure 7A). Expression of an OXR1 fragment, start-
ing with sequences encoded by exon 8 (pMV1266), fully
suppressed Lac+ reversion frequencies of MV6543 by
99.4%, down to levels exhibited by wild type E. coli
(Figure 7A; [34]). Plasmid pKM406, which encodes an
OXR1 derivative that is largely deleted of exon 8, did
not suppress the mutagenic activity of MV6543, consist-
ent with the papillation assay. In large part, this result is
likely due to the inability of this construct to produce a
stable protein (see Figure 6C). Plasmid pKM398, deleted
of exon 8 sequences encoding residues 9–36, also
showed no suppression of mutagenic activity in the Lac+
reversion assay. This result differs from the papillation
Table 1 Papillation results from plasmids expressing OXR1 derivatives
Plasmid # Description Promoter; terminators Papillation suppression
pMV520 Exon 7 (200) – Exon 16 (45) Ptrc +
C-terminal deletions: regions present*
pMV1248 exon 7 (200) – exon 16 (44) Ptrc +
pMV1255 exon 7 (200) – exon 15 (20) Ptrc +
pMV1256 exon 7 (200) – exon 13 (39) Ptrc +
pMV1257 exon 7 (200) – exon 13 (15) Ptrc +
pMV1258 exon 7 (200) – exon 12 (31) Ptrc +
pMV1293 exon 8 (1) – exon 13 (39) Pmac +
N-terminal deletions: regions present*
pMV1260 exon 7 (200) – exon 16 (44) Pmac; rrnT1 +
pMV1263 exon 7 (225) – exon 16 (44) Pmac; rrnT1 +
pMV1266 exon 8 (1) – exon 16 (44) Pmac; rrnT1 +
pMV1269 exon 9 (1) – exon 16 (44) Pmac; rrnT1 -
pMV1272 exon 11 (1) – exon 16 (44) Pmac; rrnT1 -
pMV1275 exon 12 (1) – exon 16 (44) Pmac; rrnT1 -
pMV1278 exon 13 (1) – exon 16 (44) Pmac; rrnT1 -
Internal deletions: regions deleted**
pMV1294 Δ exon 8 (14) – exon 11 (11) Pmac -
pMV1295 Δ exon 9 (42) – exon 13 (10) Pmac +
pMV1296 Δ exon 13 (13–39) Pmac +/−
pKM361 Δexon 8 (51) – exon 9 (16) Pmac; rrnT1 +
pKM394 Δexon 9 (29–42) Pmac; rrnT1 +
pKM398 Δexon 8 (9–36) Pmac; rrnT1 +
pKM406 Δexon 8 (9–50) Pmac; rrnT1 -
pKM407 Δexon 8 (37–50) Pmac; rrnT1 +
































































Figure 7 (A) Lac + reversion frequencies of MV6543 (MV4709 with pMS421) containing various OXR1 fragment-producing plasmids.
Cells containing plasmids were grown overnight as described in the Methods section. All cultures contained 1 mM IPTG, except ones that
contained pMV1266 and pKM407, which contained 0.1 mM IPTG (to prevent lethality that results from higher levels of expression of these OXR1
proteins). All cultures grew to saturation (2–4 x 109 cells/ml). The results are reported as the mean of 3–6 determinations for each strain; error
bars report the standard error. A t-test analysis of the values reported for pKM398 and pKM406 determined that there is no significant difference
between the two frequencies reported for these plasmids. (B) Diagram of the OXR1 fragment-producing plasmids used in the Lac+ reversion assay.
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the presence of 1 mM IPTG) did suppress papillation to
a degree (see Figure 6B). These different results for
pKM398 can be ascribed to either the greater sensitivity
of the papillation assay in measuring mutagenesis, or to
differences in the residual activity of this OXR1 deletion
mutant when grown in liquid culture (in LB) versus M9
minimal plates. Plasmid pKM407, however, deleted of
sequences encoding residues 37–50 of exon 8, inhibited
mutagenesis by 97% (close to the level exhibited by
pMV1266) consistent with the results of the papillation
assay described above.
Two other plasmids were also examined in the Lac+
reversion assay. Both pMV1258 (encoding a C-terminal
deletion of exons 13–16) and pMV1295 (expressing only
exon 8 and part of exon 13), which both showed high
levels of suppression using the paplliation assay, also
showed inhibition of mutagenesis in the Lac+ reversion
assay to 84% and 69%, respectively, of the level exhibited
by MV6543 containing the control plasmid. Again, the
lack of full suppression with these plasmids using the
Lac+ reversion assay can be attributed to the greater sen-
sitivity of the papillation assay, or to differences in
OXR1 activity of these mutants when grown in liquid
culture versus solid media. Overall, however, the results
of the papillation assays and the Lac + reversion frequen-
cies are in good agreement; that is, that exon 8-encoded
residues 9–36 play a critical role in the mutagenic sup-
pression capability of the human OXR1 protein.
Discussion
These results show that OXR1 amino acids 9–36 of exon
8 is a key region responsible for the oxidative antimuta-
tor activity of OXR1. This region is also an important
stability determinant of the OXR1 protein expression in
E. coli. While it might be concluded that this region is
simply required for stability of OXR1, with the repair
function encoded by a different region of OXR1, this
supposition is not supported by consideration of results
from all the deletion mutants. For instance, the analyses
of the C-terminal deletion mutants shown in Figure 3
reveal that exons 13–16 are not required for the anti-
oxidation activity exhibited by full length OXR1. This re-
sult was a little surprising, as this region of OXR1 shows
the highest homology among comparisons to other
OXR1 variants [24] and contains a conserved protein
domain found in a number of eukaryotic proteins with
nuclear function - the TLDc domain [37]. Sequences
present in exon 12 can also be ruled out as important
for OXR1 activity, as plasmid pMV1292 expresses a
stable protein (which includes this region), but does not
suppress papillation (Figure 2 C&D). Most revealing
however, is the result for plasmid pMV1295, which con-
tains exon 8 as the only intact exon of OXR1 and iscompletely capable of suppressing papillation (Figure 4).
Taken together, the results reported here suggest that
exon 8, especially the region encoding a large predicted
helix-turn-helix region, is the key determinant for the
oxidation resistance function of the OXR1 protein.
The human gene NCOA7 encodes a protein that
associates with the estrogen receptor, is targeted to the
nucleus, and is highly homologous to OXR1 [24,39]. The
gene is expressed in a variety of tissues, but is most
highly expressed in neurons. It has been proposed that
NCOA7, by binding to the estrogen receptor, might alle-
viate the oxidative damage that results from estradiol
metabolism [34]. Other enzymes involved in the repair
of DNA damage have also been identified that bind to
the estrogen receptor [40-42] and may play a similar role
in protecting DNA from oxidative damage. Durand et al.
[34] showed that C-terminal fragments of NCOA7 con-
taining the TLDc domain were capable of oxidative
damage repair in E. coli. Of note, however, is that the
fragment of NCOA7 used in that assay also contained
most of exon 9, the exon homologous to OXR1 exon 8
examined in this report. An alignment of these two
exons is shown in Figure 5B. The C-terminal fragment
of NCOA7 that was competent for oxidative repair in E.
coli started with the methionine at position 15 of exon 9.
At this position, the C-terminal fragment of NCOA7
contains the regions most homologous to OXR1 exon 8,
the exon described here as being critical for OXR1 oxi-
dative damage suppression. Although not part of the
TLDc domain (which in OXR1 starts near the end of se-
quence encoded in exon 12) a comparison of OXR1
sequences from a variety of organisms shows that exon
8 is highly conserved, especially among higher
eukaryotes.
OXR1 and its close homolog NCOA7 are produced in
many different forms either as a result of alternative spli-
cing, or alternative transcription start sites. Most of
these isoforms include exon 8 of OXR1, or its counter-
part (exon 9) of NCOA7, indicating that their antioxi-
dant functions are key features of the gene products.
However, there are several isoforms that include only
the C-terminal TLDc domain that lack exon 8. The best
characterized of these isoforms is the OXR1 C7C variant
originally described by Fischer et al.. [43] and its human
counterpart. This variant includes OXR1 exon 10, which
is not found in other variants of OXR1. The human
form of this variant of OXR1 lacks antioxidant activity,
as no suppression of oxidative mutagenesis is seen when
this protein is highly expressed in the E. coli mutM
mutY strain (unpublished observations). This result
eliminates the possibility that exon 10 can replace the
oxidation resistance function of exon 8. These results
suggest that in addition to the conserved oxidation re-
sistance function, these highly conserved proteins may
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ized and that this hypothetical function is contained
within the highly conserved C-terminal TLDc domain.
Oliver et al. [32] have recently reported that loss of
mouse OXR1 (mOXR1) resulted in the onset of an
ataxia phenotype two weeks after birth in bel mice, fol-
lowed by death within the first month of life. The
authors found that the cerebellar granual cell layer
(GCL) of these mice were sensitive to hydrogen peroxide
more than normal controls, an effect that could be
reversed by lentiviral expression of an OXR1 transgene.
Notably, using a gene-trap construct, they found that
in vivo expression of the C-terminal region of mOXR1
(mOXR1-C), which corresponds to exons 12–16 of
hOXR1, was capable of reversing the neurological
phenotype and early death of bel mouse mutant. In
addition, they show that mOXR1-C expression could
protect both wild-type and bel mutant GCL cells from
hydrogen peroxide-induced apoptosis. On the contrary,
we find that the C-terminal region of the hOXR1 was
neither necessary or sufficient for suppression of oxida-
tive damage in E. coli, and instead, that the function
required for the antimutator phenotype resides in exon
8, which is present in both full-length and intermediate
splice variants of hOXR1.
Combining the results of both studies, a model
emerges regarding the different functional characteristics
of the mammalian OXR1 protein. The TLDc domain in
the C-terminus of mOXR1 is clearly required for a key
function of OXR1 that protects cells from oxidative
damage, as shown by the study of Oliver et al. [32].
These authors go on to show that the mOXR1-C do-
main can interact with H2O2 via oxidation of a reactive
cysteine (Cys753), suggesting that OXR1’s oxidative anti-
mutator function may be the result of a direct inter-
action between the protein and reactive oxygen species.
However, as the authors noted, the rate constant for this
reaction was thousands of times lower relative to antiox-
idants that work in this manner (such as catalase and
peroxiredoxins), leading them to suspect that the TLDc
domain of mOXR1 has another type of function, or per-
haps operates in a regulatory capacity. A regulatory role
of OXR1 has been suggested by Jaramillo-Gutierrez
et al. [26] who showed that silencing of OXR1 in mos-
quitoes resulted in lower levels of transcripts coding for
enzymes such as catalase and glutathione peroxidase,
proteins that act directly in detoxification of ROS. In this
study, using our E. coli assay, we find that an oxidative anti-
mutator function is not found in the hOXR1 C-terminal re-
gion, leading to the greater likelihood that this domain may
instead have regulatory role, perhaps after an interaction
with certain types of reactive oxygen species. Along these
lines, the dispensability of the hOXR1 C-terminal region in
our E. coli assay is not unexpected if the TLDc domain’sprincipal role in mammalian cells is to regulate antioxida-
tive operons, an effect not likely reproducible in E. coli.
We favor a model of hOXR1 where an antioxidant ac-
tivity is encoded by exon 8, with the C-terminal domain
conferring a regulatory region that responds to ROS. At
least in E. coli, the proposed C-terminal regulatory re-
gion is not required for antioxidant function. Splice var-
iants that include full length or intermediate species of
hOXR1 may then reflect the need for both antioxidant
activity and antioxidant-regulatory functions, whereas in
tissues where only the short C-terminal region of
hOXR1 is present may require only the regulatory fea-
ture of the OXR1 protein to protect from ROS. The
study by Oliver et al. [32] showed that the shorter
mOXR1-C form is present in the brain at low levels,
though it is as highly expressed in the cerebellum as full
length mOXR1. Such differences may reflect the need
for regulatory capabilities of mOXR1 more so in the
cerebellum than in the rest of the brain, where both an
oxidative antimutator function and a regulatory region
are required. As mentioned in the Introduction, these
authors also reported an upregulation of intermediate
forms of OXR1 in ALS human biopsy samples, as well
as in SOD1 mutant mice (a mouse model of ALS). The
intermediate forms of OXR1 contain the upstream oxi-
dative antimutator function we have identified here in
exon 8 and may reflect the need for this activity as a
protective function in ALS patients. It would be interest-
ing to know if mutations in the hOXR1 gene also play a
role in sporadic cases of ALS.
What does OXR1 the exon 8-encoding function do?
The region of exon 8 required for oxidation resistance
shares homology only with other members of the OXR
family of proteins suggesting they have a unique function
not shared with other proteins that contribute to oxida-
tive stress resistance. However, it has been observed that
OXR1 can suppress mutagenesis in bacteria, indicating it
does not require additional human proteins for function
and can suppress mutagenesis resulting from mutations
in genes inactivating several different types of oxidative
lesions [24]. These results make it more likely that OXR1
exon 8-encoded region prevents rather than repairs oxi-
dative damage, since oxidative damage repair enzymes
typically recognize only a single, or a set of structurally
similar lesions. Such a role for OXR1 as an antioxidant
protein is further supported by studies of oxr1 deletion
mutants of yeast, which exhibit elevated levels or ROS,
suggesting its function is to reduce ROS levels
(Fenton and Volkert, unpublished results).
Conclusion
The human OXR1 gene exon 8 encodes a function
required for the suppression of oxidative damage. This
oxidative resistance function is distinct from the highly
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of OXR1. A model is proposed that OXR1 consist of
two separable functions involved in oxidative resistance:
a C-terminal domain that has a regulatory role in indu-
cing oxidative resistance functions in response to oxida-
tive damage, and an internal region of the protein
encoded by exon 8 that possesses a antimutator
“protective” function against reactive oxygen species.Methods
Plasmid constructions
Plasmid pMV520 has been described [24]. C-terminal
deletion mutants of OXR1 were generated by cloning
PCR-generated fragments of OXR1 into the EcoR1 and
XmaI sites of expression vector pTrc99a. In these plas-
mids, OXR1 fragments are expressed from the Ptrc pro-
moter. The endpoints of the OXR1 deletions are
indicated by the arrows in Figure 1. Plasmids containing
N-terminal deletions of OXR1 were generated by clon-
ing PCR-generated fragments of OXR1 into the NdeI
and SacI backbone of pTP905 (A. Poteete, unpublished).
In these constructs, OXR1 fragments are exp-
ressed from the IPTG-inducible Pmac promoter (P mod-
erate lacUV5-like) [44]. The Pmac promoter sequence
(TTTACATTGTGAGCGGATAACAATATAAT) contains
a lac operator (italicized) between the −35 and −10
regions. These OXR1 N-terminal deletion vectors also
contain an rrnT1 terminator downstream of the gene
fragments, which confers greater stability to transcripts
resulting in higher expression levels (unpublished obser-
vations). Two of these vectors (pMV1260 and
pMV1263) start within the latter part of exon 7; the
other plasmids in this series were constructed by adding
a start codon in front of the first codon of exons 8, 9,
11, 12 and 13, respectively.
A plasmid pMV1293 was constructed that encoded an
OXR1 fragment starting with exon 8 and ending at resi-
due 39 of exon 13. A PCR product (using a derivative of
pMV520 as a template) was cloned into the NdeI-XbaI
backbone of pMV1266, resulting in removal of the rrn
T1 terminator. A series of internal (in-frame) deletions
of pMV1293 were constructed by digestion of the plas-
mid with restriction enzymes and religation of the
resulting backbone. Plasmids pMV1294, pMV1295 and
pMV1296 were generated by digestion of pMV1293 with
ClaI, MfeI and NcoI, respectively; the ClaI digestion was
filled-in by T4 polymerase and dNTPs. The backbone
(ori-containing) fragments were religated and trans-
formed into competent E. coli cells overexpressing LacI
(W3110 lacIq). The resulting plasmids contain in-frame
deletions of one or more of the OXR1 exons present in
pMV1293; the residues absent in the OXR1 proteins
encoded by these plasmids (relative to pMV1293) arelisted in Table 1. Plasmid dilutions of pMV520 were
used as a template for all PCR reactions.
A second set of internal deletions within a full length
OXR1 protein (defined here as the protein encoded by
the exons listed in Table 1, with the exceptions of exons
7 and 10) was generated by λ Red recombineering
[45,46]. Cassettes encoding a kanamycin-resistant deter-
minant flanked by NotI sites (generated by PCR) were
recombined into pMV1266 resulting in various deletions
of exons 8 and/or 9. An extra G nucleotide was included
in one of the primers, so that following digestion of the
modified pMV1266 plasmids with NotI and religation of
the linearized plasmid, regions of OXR1 containing exon
8 and/or 9 were replaced with GCGGCCGCG. The
resulting plasmids thus encoded in-frame deletions of
OXR1, where the deleted regions of the OXR1 protein
were replaced with 3 alanines. A summary of all the
plasmids constructed for this study appears in Table 1.
All plasmids modifications constructed in this study
were verified by sequencing. Primers sequences used to
generate the plasmid constructs are available upon
request.
Mutagenesis assays
Full-length OXR1 protein and various truncations/
mutations of OXR1 were expressed in strain MV4709
(mutM::Tn19 mutY::cat), which also carries the mutant
lacZ cc104 allele [47]. This lacZ allele reverts to wild
type by a GC to TA transversion, a common mutation
known to occur during oxidative stress due to the high
levels of 8-oxoG formation. Thus, one can follow the
spontaneous oxidative damage occurring in this strain
by the presence of blue papillae in single white colonies
on plates containing Xgal and IPTG [47]. In order to
moderate expression of OXR1 and mutant derivatives,
host cells also contained the compatible plasmid
pMS421 (a pGB2 derivative) that overexpresses the LacI
repressor. Fresh cultures of MV4709 (mutM mutY)
containing pMS421 (MV6543) and plasmids expressing
wild type and various deletions of OXR1 were grown
from overnight stocks to 2 x 108 cells/ml in LB media
containing 100 μg/ml ampicillin, 40 μg/ml spectino-
mycin and 20 μg/ml streptomycin. Dilutions of the
cultures were spot titered on minimal plates containing
0.2% glucose, 1X A salts, 1 mM MgSO4, 0.5 mg/ml
phenyl-β-D-galactopyranosie (P-Gal), 50 μg/ml carbeni-
cillin, 40 μg/ml X-gal and various concentrations of
IPTG (see figure legends). Mutagenesis was observed by
the high density of blue papillae present in single white
Lac + colonies; suppression of papillation is indicative of
OXR1 activity.
The Lac+ reversion assay was performed essentially as
described by Poteete [48], with some modifications.
Small colonies of MV6543 cells (MV4709 with pMS421-
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producing plasmids (AmpR), were picked from LB plates
containing ampicillin (100 μg/ml), spectinomycin
(20 μg/ml), streptomycin (10 μg/ml), and resuspended in
LB containing these same concentrations of drugs, and
in addition, either 0.1 mM or 1 mM IPTG (see legend to
Figure 7). Between 3–6 colonies were picked for each
strain containing an OXR1 fragment-producing plasmid.
The cultures were grown overnight at 37oC with aer-
ation. Cells were collected by centrifugation and resus-
pended in 1 volume of 1x M9 salts. Undiluted and
diluted samples of cells (between 107 and 108 total) were
plated on M9 minimal lactose plates to determine the
number of Lac + revertants, and on LB plates to deter-
mine the total number of cells plated. M9 minimal plates
contained 0.2% lactose and were supplemented with
thiamine at a concentration of 5 μg/ml . Lac + reversion
frequencies are reported as the number of Lac + rever-
tants per 108 cells plated. To reduce background growth
on the minimal lactose plates, 109 scavenger cells,
TP889 (ΔlacZ::cat) [48] were plated along with various
amounts of the test cultures. The scavenger cells cannot
revert to Lac+, but deplete the plates of trace energy
sources preventing late-arising colonies from appearing,
and in turn, lead to more accurate frequencies of Lac +
reversion. The scavenger cells were prepared by growing
a 50 ml culture of TP889 in LB overnight, collecting
cells by centrifugation, washing once with cold 1x M9
salts and resuspending in 5 ml cold 1x M9 salts; a total
of 100 μl of scavenger cells were plated with each of the
test strains on M9 minimal lactose plates.OXR1 Fragment production in vivo
SDS-polyacrylamide gels were used to assess the presence
of stable OXR1 protein fragments. Cultures (5 ml) were
grown to 2 x 108 cells/ml in LB containing 100 μg/ml
ampicillin, 40 μg/ml spectinomycin and 20 μg/ml strepto-
mycin. IPTG was added to 1 mM concentration and cells
were aerated by rolling for 2.5 hours. The cultures were
then collected by centrifugation and resuspended in
100 μl of 50 mM Tris–HCl, 100 mM NaCl, 1 mM EDTA,
10% glycerol. Cells suspensions were diluted with an equal
volume of H20 and then mixed with an equal amount of
2x SDS buffer. Samples were boiled for 3 minutes, run
overnight at 50 volts on 10% polyacrylamide gels using the
Tricine system [49] or 12% polyacrylamide using Tris buf-
fers as previously described [50]. Gels were stained with
Coomassie Blue. All the protein bands identified in this
study as OXR1 full-length protein or proteins fragments
were dependent upon the addition of IPTG. Cells not
grown in the presence of IPTG showed the same pattern
as the pBR322 control. A plasmid derivative of pMV1266
that had a frameshift mutation in the OXR1 gene resultedin the same pattern on these SDS-PAGE gels as pBR322-
containing cells.
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